By VETTAPHARMA reporter – Derek Roche: Novartis will present new data on Rhapsido® (remibrutinib) at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Philadelphia, Pennsylvania, taking place from February 27 to March 2, 2026. The presentations will highlight analyses from the Phase III REMIX-1 and REMIX-2 trials in chronic spontaneous urticaria (CSU) and initial Phase II data in IgE-mediated peanut allergy, demonstrating the investigational BTK inhibitor’s broader potential beyond CSU.
Novartis will feature five key abstracts evaluating remibrutinib at the congress. These include disease control and early symptom relief from the Phase III REMIX-1 and REMIX-2 studies in CSU, as well as oral presentations of Phase II results assessing efficacy and safety in peanut allergy. Plans are underway to initiate a Phase III program in food allergy in 2026, reinforcing remibrutinib’s potential across a range of allergic and immune-mediated conditions.
In the CSU analyses, pooled results will focus on how remibrutinib impacts disease control and provides fast symptom relief within the first week of treatment, as measured by daily urticaria activity scores (UAS). The abstracts accepted include presentations on improved disease control, rapid relief of itch and hives, and health care resource utilization by level of disease control in CSU patients.
Angelika Jahreis, Global Head of Immunology Development at Novartis, commented that the food allergy data “further strengthen the evidence supporting remibrutinib as a novel, well-tolerated, oral option for patients with allergic and immune-mediated diseases,” complementing the recent U.S. Food and Drug Administration approval for CSU and highlighting remibrutinib’s broader therapeutic potential.
Regulatory reviews for remibrutinib in CSU continue in the European Union and Japan, and the therapy is also being evaluated in additional immunology indications, including chronic inducible urticaria (CIndU) and hidradenitis suppurativa (HS).
